ACM
TEVA icon

Anfield Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Anfield Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.2K Hold
73
– – ﹤0.01% 579
2025
Q4 		$2.28K Hold
73
– – ﹤0.01% 461
2025
Q3 		$1.48K Buy
+73
New +$1.28K ﹤0.01% 494

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Anfield Capital Management's TEVA Position: Q1 2026 in Review

Anfield Capital Management held its Teva Pharmaceuticals (TEVA) position steady in Q1 2026 at 73 shares worth $2.2K. The position accounts for ﹤0.01% of the portfolio, ranked #579.

Anfield Capital Management first reported a position in TEVA in Q3 2025 and has held it in 3 quarters since. The position peaked at $2.28K in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Anfield Capital Management held 73 shares of Teva Pharmaceuticals worth $2.2K as of Q1 2026.
  • Anfield Capital Management left its Teva Pharmaceuticals share count unchanged in Q1 2026.
  • Teva Pharmaceuticals made up ﹤0.01% of Anfield Capital Management's portfolio in Q1 2026, its #579 holding.
  • Anfield Capital Management first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Anfield Capital Management's Teva Pharmaceuticals position peaked at $2.28K in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.